sarepta therapeutics

Market News

Sarepta Therapeutics CEO Ingram Announces Retirement by Year‑End
ByAmna Habib February 26, 2026February 26, 2026

Biotech firm Sarepta Therapeutics made headlines recently after its Chief Executive Officer Chuck Ingram announced he will retire by the end of the year. This leadership change has drawn attention from investors, biotech analysts, and the broader stock market as shareholders assess what it means for the company’s future strategy and performance. Sarepta Therapeutics is…

Read More Sarepta Therapeutics CEO Ingram Announces Retirement by Year‑End
US Stocks

Sarepta Therapeutics Stock Tumbles 42% Following Second Drug‑Linked Death Report
ByAmna Habib June 17, 2025June 17, 2025

Shares of Sarepta Therapeutics Stock tumbled 42% after the biotech company reported a second death connected to its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys. The news rattled investors, erasing market value and dragging the stock to nine-year lows. This second fatality has raised serious concerns over the safety of the drug, especially for non-ambulatory…

Read More Sarepta Therapeutics Stock Tumbles 42% Following Second Drug‑Linked Death Report